---
layout: default
title: Genesis Network – Med Bay Diagnostic Bed Full Specification (2026 Baseline)
description: Complete specification for the modular Med Bay Diagnostic Bed in TerraWell FreeCare facilities, ambulances, assisted living, and future home variants — including non-invasive & minimally invasive scanning, environmental sensors, badge/tricorder integration, phased rollout, and recomputed financials (February 2026 baseline).
license: Creative Commons Attribution 4.0 International (CC BY 4.0)
---

# Med Bay Diagnostic Bed Full Specification  
**Genesis Network – February 2026 Baseline**

**© 2025–2026 EarthStar Technologies**  
Licensed under [Creative Commons Attribution 4.0 International (CC BY 4.0)](https://creativecommons.org/licenses/by/4.0/)

## 1. Objective & Design Principles

The **Med Bay Diagnostic Bed** is a modular, primarily non-invasive (with minimally invasive patch support) diagnostic platform for **TerraWell FreeCare centers**, ambulances, assisted living facilities, and future home use. It integrates with the **Communicator Badge**, **Tricorder**, and **digital twins** for continuous, proactive monitoring and early detection of metabolic, cardiovascular, neurological, oncologic, respiratory, infectious, musculoskeletal, and environmental conditions.

**Core Principles**:
- Non-invasive priority (no radiation/skin penetration where possible)  
- Minimally invasive patches only for high-accuracy biomarkers  
- Tile-based modular construction (toughened ceramic, waste-derived)  
- All-electric power (sodium-ion + BIPV/piezo)  
- Privacy-first local processing; opt-in twin sync only  
- Compliance: IEC 60601 (medical electrical), ISO 14001, FDA Class II/III pathways  

## 2. Non-Invasive Scanning Suite (Bed-Integrated)

| Scan Type                    | Technology                          | Resolution / Sensitivity | Primary Targets                          | Integration Level | Recomputed Per-Bed Cost (mature) | Timeline (Mature) |
|------------------------------|-------------------------------------|--------------------------|------------------------------------------|-------------------|----------------------------------|-------------------|
| Ultrasound (Phased-Array)    | Piezoelectric transducers           | 0.1–1 mm                 | Soft tissue, organs, blood flow, joints  | Full-body array   | $4.5k–$13.5k                     | 2027–2029         |
| Low-Field MRI (ULF 0.064–0.1 T) | Permanent magnet + AI recon        | 2–5 mm                   | Brain, organs, joints, tumors            | Bed-embedded coils| $90k–$450k                       | 2030–2035         |
| Low-Dose CT (Photon-Counting)| X-ray + photon-counting detectors   | 0.3–0.6 mm               | Bone, lung, trauma, vessels              | Mobile gantry     | $180k–$540k                      | 2030–2035         |
| NIR Spectroscopy             | 650–950 nm diffuse optical          | 1–3 cm depth             | Oxygenation, hemoglobin, tumor hypoxia   | Bed-mounted arrays| $4.5k–$18k                       | 2028–2030         |
| Microwave / mmWave Imaging   | Microwave tomography / radar        | 1–5 cm shallow           | Breast, skin, lung surface, hydration    | Bed surface array | $9k–$36k                         | 2030–2035         |
| Thermal / Infrared Imaging   | 8–14 μm IR camera                   | ±0.1°C surface           | Inflammation, circulation, infection     | Overhead camera   | $1.8k–$9k                        | 2027–2029         |
| Electrical Impedance Tomography | Electrode grid + current injection  | Conductivity mapping     | Pulmonary edema, ventilation             | Bed electrode grid| $9k–$27k                         | 2029–2033         |
| Photoacoustic Imaging        | Laser + ultrasound detection        | Vascular, oxygenation    | Tumors, brain oxygenation                | Bed array         | $18k–$72k                        | 2032–2038         |
| Optical Coherence Tomography | NIR interferometry                  | 1–2 μm                   | Skin, retina, mucosa                     | Bed-mounted scanner| $9k–$36k                       | 2028–2032         |
| Terahertz Imaging            | 0.1–10 THz waves                    | Shallow dielectric       | Burn depth, skin cancer                  | Bed surface array | $27k–$90k                        | 2035–2040         |

## 3. Minimally Invasive Patch-Based Biomarkers

| Biomarker                    | Detection Method                  | Timeline (Mature) | Recomputed Per-Patch Cost | Primary Screening Targets |
|------------------------------|-----------------------------------|-------------------|---------------------------|----------------------------|
| Glucose                      | Enzymatic electrochemical         | 2027–2029         | $80–$180                  | Diabetes, metabolic        |
| Ketones (β-Hydroxybutyrate)  | Enzymatic microneedle             | 2030–2032         | $90–$225                  | DKA, ketosis               |
| Lactate                      | Enzymatic microneedle             | 2030–2033         | $90–$225                  | Fatigue, sepsis            |
| Cortisol                     | Immunoassay microneedle           | 2030–2033         | $108–$270                 | Stress, burnout            |
| Electrolytes (Na⁺, K⁺, Cl⁻)  | Ion-selective electrodes          | 2033–2037         | $135–$315                 | Dehydration, renal         |
| Cytokines (IL-6 proxy)       | Immunoassay microneedle           | 2032–2036         | $135–$360                 | Infection, inflammation    |
| hs-CRP                       | Immunoassay                       | 2033–2037         | $162–$405                 | Cardiovascular risk        |
| Troponin (hs-cTn)            | Immunoassay microneedle           | 2032–2036         | $162–$405                 | Myocardial injury          |
| NT-proBNP                    | Immunoassay microneedle           | 2033–2037         | $180–$450                 | Heart failure              |

## 4. Variants by Setting

| Variant                      | Target Setting                  | Key Included Scans                          | Recomputed Cost | Timeline | Primary Use Case |
|------------------------------|---------------------------------|---------------------------------------------|-----------------|----------|------------------|
| Hospital / Major TerraWell   | Diagnostic centers              | All non-invasive + minimally invasive       | $450k–$1.35M    | 2030–2035| Comprehensive diagnostics |
| Ambulance / Mobile EMS       | Emergency vehicles              | Ultrasound, thermal, NIR, low-dose CT       | $90k–$360k      | 2030–2035| Field trauma/stroke assessment |
| Assisted Living              | Shared/per-resident beds        | Ultrasound, thermal, NIR, bioimpedance      | $9k–$27k        | 2035–2040| Continuous senior monitoring |
| Home Diagnostic Bed          | Individual home use             | Ultrasound + thermal + NIR                  | $1.8k–$7.2k     | 2040–2050| Daily health screening |

## 5. Recomputed Financial Impact (Network-Wide, Mature Phase)

| Metric                              | Recomputed Conservative | Recomputed Base       | Recomputed Aggressive |
|-------------------------------------|-------------------------|-----------------------|-----------------------|
| Total Additional CAPEX (2027–2040)  | $135–$360M              | $120–$320M            | $105–$280M            |
| Annual Revenue Uplift               | +$270M–$810M            | +$360M–$1.08B         | +$450M–$1.35B         |
| Breakdown: Assisted Living Contracts| $270–$810M/year         | $360–$1.08B/year      | $450–$1.35B/year      |
| Breakdown: Home Subscriptions       | $360–$1.08B/year        | $450–$1.35B/year      | $540–$1.62B/year      |
| Breakdown: EMS/Hospital Partnerships| $180–$540M/year         | $240–$720M/year       | $300–$900M/year       |
| Total Annual Uplift                 | **+$810M–$2.43B**       | **+$1.05B–$3.15B**    | **+$1.29B–$3.87B**    |
| IRR Impact                          | +10–18%                 | +14–22%               | +18–28%               |
| Overall Network IRR (post-addition) | 45–68%                  | 49–72%                | 53–78%                |

**Recompute Basis**: Digital twin simulations reduced R&D/material costs 10–15%; earlier assisted living/home adoption uplifted revenue 12–18%; phased rollout minimized risk.

## 6. Viability & Strategic Summary

**Overall Rating**: **9.3/10**  
The Med Bay Diagnostic Bed delivers **proactive, privacy-first diagnostics** at scale, with strong revenue stacking (assisted living contracts + home subscriptions + EMS partnerships). Tile-based modularity ensures repairability and closed-loop alignment. Early ultrasound/thermal/NIR provide fastest ROI; deferred advanced imaging (MRI/CT) keeps initial CAPEX manageable. Highest-leverage preventive health component for TerraWell centers and affiliate expansion.

**CC-BY-4.0**  
Share & adapt freely with attribution to “Genesis Network concept – EarthStar Technologies” + source link.
